Which two neurotransmitters are primarily improved by the use of SNRIs?

The correct response highlights that SNRIs, or serotonin-norepinephrine reuptake inhibitors, primarily enhance the activity of serotonin and norepinephrine in the brain. These two neurotransmitters play vital roles in regulating mood, emotions, and overall mental health.

SNRIs work by blocking the reuptake of serotonin and norepinephrine at the synaptic cleft, leading to increased levels of these neurotransmitters in the brain. This boost can help alleviate symptoms of depression and anxiety, which are often linked to deficiencies or imbalances in serotonin and norepinephrine.

Dopamine, while important in various neurological processes, is not a primary target of SNRIs, which is why options that include dopamine are not correct. Additionally, GABA is primarily an inhibitory neurotransmitter, and while it is essential for mood regulation, it is not directly improved by SNRIs either. Thus, the enhancement of serotonin and norepinephrine stands out as the key mechanism of action for SNRIs, making this choice the most accurate representation of their pharmacological effects.